News

Christian Lienhardt Discusses the Newly Launched TB-PACTS Database

Christian Lienhardt, from WHO, discusses the launch of TB-PACTS, the new data-sharing platform for TB clinical trials. This marks the beginning of an exciting new tool in the fight against TB. Announced on April 18th, TB-PACTS combines clinical trial data from Critical Path Institute (C-Path), the Special Programme for Research and Training in Tropical Diseases (TDR), TB Alliance, and St. George’s, University of London. Hosted on the C-PATH website, it strives to standardize all Phase III tuberculosis clinical trial data. According to the website, “researchers can access and analyze data in aggregate, or filter and view individual patient-level data from the REMoxTB, RIFAQUIN and OFLUTUB clinical trials”.

TB-PACTS, which stands for TB-Platform for Aggregation of Clinical TB Studies, is accessible to researchers after registering an online application. The website informs users it may take up to 4 weeks for the application to be processed. Once registered users are able and encouraged to contribute data as well. The site assures users that they retain ownership of their data and that the platform is secure.

As Dr. Lienhardt discusses, having a larger database improves and refines the ability to analyze the data. It provides an increased sample size, an opportunity to perform analysis of specific populations, and an increased likelihood of finding commonalities that were not picked up in the single trials.

Related Links

TB-PACTS Website

Christian Lienhardt Discusses TB-PACTS

TB-PACTS Press Release

More News
9 Jul 2020
Earlier this week, Johnson & Johnson announced a reduction in the price for bedaquiline in low- and middle-income countries, as part of a collaboration with the Stop TB Partnership's Global Drug Facility (GDF). The immediate change in price will make bedaquiline available through the GDF at the...
18 Jun 2020
On May 21st, Antimicrbial Agents and Chemotherapy published an article on Otsuka's novel anti-tuberculosis compound, OPC-167832. This molecule, a DprE1 inhibitor, demonstrated potent bactericidal activity and exhibited significant combination effects in 2-drug combinations with delamanid,...
17 Jun 2020
On March 25th, Qurient announced the results of their Phase 2 Clinical Trial (ClinicalTrials.gov number, NCT03563599 ), which was a prospective, randomized, open-label trial for proof of concept in humans of their novel anti-tuberculosis drug, Telacebec (Q203). The trial involved 61 newly-diagnosed...